Physician profile
Ivan Patrick Maillard
NPI 1568403269
$5,798.50
in general payments reported to CMS, 2019-2025
4 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.29 · 2020: $88.03 · 2023: $1,420 · 2024: $4,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,980 · Travel and Lodging: $537 · Food and Beverage: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,980.00 |
| Travel and Lodging | $537.15 |
| Food and Beverage | $131.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,228.18 | 2024 | |
| Genentech USA, INC. | $1,420.00 | 2023 | |
| Regeneron Pharmaceuticals, INC. | $150.32 | 2019-2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Maillard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.